Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Luecke, E; Ganzert, C; Vielhaber, S; Haybaeck, J; Jechorek, D; Mawrin, C; Schreiber, J.
Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma.
Clin Lung Cancer. 2020; 21(4):e246-e249-e246-e249
Doi: 10.1016/j.cllc.2020.01.008
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Haybäck Johannes
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Immune checkpoint inhibitors (ICIs) substantially improve prognosis in patients with non-small-cell lung cancer. Myositis and myocarditis are very rare, but potentially life threatening, immune-related adverse events associated with ICI therapy. Patients with thymic epithelial tumors are at increased risk for these severe complications. A history of cured thymic epithelial tumors without recurrence seems to be a relevant risk for patients treated with ICIs irrespective of the indication. (C) 2020 Elsevier Inc. All rights reserved.
- Find related publications in this database (Keywords)
- Immune checkpoint inhibition
- Immune-related adverse events
- Myocarditis
- T-cell receptor clones
- Treatment of autoimmune toxicities